These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 22234381)
1. Influence of risperidone on balance control in young healthy individuals. Corbeil P; Rodrigue J; Simoneau M; Cohen H; Pourcher E Psychopharmacology (Berl); 2012 Jul; 222(1):59-69. PubMed ID: 22234381 [TBL] [Abstract][Full Text] [Related]
2. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871 [TBL] [Abstract][Full Text] [Related]
3. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Heck AH; Haffmans PM; de Groot IW; Hoencamp E Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421 [TBL] [Abstract][Full Text] [Related]
5. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Tada M; Shirakawa K; Matsuoka N; Mutoh S Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255 [TBL] [Abstract][Full Text] [Related]
6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
7. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. Fleischhacker WW; Lemmens P; van Baelen B Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401 [TBL] [Abstract][Full Text] [Related]
8. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study. Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269 [TBL] [Abstract][Full Text] [Related]
9. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. Katz IR; Jeste DV; Mintzer JE; Clyde C; Napolitano J; Brecher M J Clin Psychiatry; 1999 Feb; 60(2):107-15. PubMed ID: 10084637 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study. Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622 [TBL] [Abstract][Full Text] [Related]
11. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. Rainer MK; Masching AJ; Ertl MG; Kraxberger E; Haushofer M J Clin Psychiatry; 2001 Nov; 62(11):894-900. PubMed ID: 11775050 [TBL] [Abstract][Full Text] [Related]
12. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976 [TBL] [Abstract][Full Text] [Related]
14. Re: Extrapyramidal side effects with low-dose risperidone. Pies R Can J Psychiatry; 1997 Oct; 42(8):881. PubMed ID: 9356779 [No Abstract] [Full Text] [Related]
15. No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial. Park CH; Park TW; Yang JC; Lee KH; Huang GB; Tong Z; Park MS; Chung YC Int Clin Psychopharmacol; 2012 Mar; 27(2):114-20. PubMed ID: 22241281 [TBL] [Abstract][Full Text] [Related]
16. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Miller CH; Mohr F; Umbricht D; Woerner M; Fleischhacker WW; Lieberman JA J Clin Psychiatry; 1998 Feb; 59(2):69-75. PubMed ID: 9501888 [TBL] [Abstract][Full Text] [Related]
17. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Mas S; Gassó P; Fernández de Bobadilla R; Arnaiz JA; Bernardo M; Lafuente A Hum Psychopharmacol; 2013 Nov; 28(6):586-93. PubMed ID: 24519692 [TBL] [Abstract][Full Text] [Related]
18. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. Haas M; Karcher K; Pandina GJ J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643 [TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121 [TBL] [Abstract][Full Text] [Related]